drugset / Trial / NCT06054477
Study of ALE.C04 in Patients With Head and Neck Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety profile of ALE.C04 monotherapy and in combination with pembrolizumab, to characterize pharmacokinetics profile of ALE.C04, recommended Phase II dose (RP2D) for ALE.C04 in combination with pembrolizumab and to assess anti-tumor activity of ALE.C04 in combination with pembrolizumab in patients with Head and Neck Cancer.
Timeline
- Start
- 2023-10-30
- Primary completion
- 2025-02-12
- Completion
- 2025-02-12
Outcome
Outcome not reported
Stopped: “Reprioritization of Trial”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ECLUTATUG | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |